Zebra Biologics, Scripps Research Institute deal
The institute granted newco Zebra Biologics exclusive, worldwide rights to IP covering a platform to generate and select agonist and antagonist antibodies from functional screens using a modified combinatorial library approach and to a portfolio of undisclosed preclinical compounds. Zebra said it is providing undisclosed funding to Richard Lerner's lab at the institute for two to five years but said the funding is renewable. The newco said it also will have rights to technologies and products developed in the lab. The institute is eligible for undisclosed milestones and royalties. Zebra declined to disclose financial details. The newco, which was founded in July 2013, said it has programs for metabolic disease, an immune therapy and an antiviral, but said its long-term focus will be virology. ...